TCW Group Boosts Stake in Amgen by 12.8% in Q2

TCW Group Inc., an institutional investor, disclosed its significant position in Amgen Inc. (NASDAQ:AMGN) through its most recent 13F filing with the Securities and Exchange Commission.

In the second quarter, TCW Group increased its stake in Amgen by 12.8% by acquiring an additional 3,222 shares. The firm now owns 28,369 shares of the medical research company's stock, valued at $10,273,000 as of its latest SEC filing.

TCW Group is not alone in its investment in Amgen, as several other institutional investors have also raised their stakes in the company during the fourth quarter. Anfield Capital Management LLC, for example, increased its stake by 1,000% and now owns 77 shares valued at $25,000.

Amgen has set its FY 2026 guidance at 22.300-23.500 EPS and is expected to post $22.78 earnings per share for the current fiscal year. The company also recently declared a quarterly dividend of $2.52, representing a 2.4% yield.